Daljeet Kohli, head- research at IndiaNivesh Securities, says Jubilant Life Sciences' fourth quarter margins of its pharma and chemicals businesses were in line with expectations. The stock looks attractive at current levels and is expected to go up to Rs 495, he adds.
